Top Markets
Coin of the day
Algernon Pharmaceuticals Inc. Algernon Pharmaceuticals Inc.

Algernon Pharmaceuticals Inc.

AGN
株式のランク #38375
Algernon Pharmaceuticals Inc. is a clinical-stage pharmaceutical company... Algernon Pharmaceuticals Inc. is a clinical-stage pharmaceutical company dedicated to discovering and developing new treatments. Their research and development efforts concentrate on a range of serious conditions, including non-alcoholic steatohepatitis, chronic kidney disease, inflammatory bowel disease, idiopathic pulmonary fibrosis, chronic cough, and acute lung injury associated with COVID-19, operating across Canada and Australia. The company's primary drug candidate, NP-120, acts as an N-methyl-d-aspartate (NMDA) receptor glutamate antagonist. This compound specifically targets the NMDA-type subunit 2B (Glu2NB) and also demonstrates agonist activity for the Sigma-1 receptor, a chaperone protein elevated during endoplasmic reticulum stress. Furthermore, Algernon is advancing AP-188, a psychedelic agent from the tryptamine family, for treating ischemic stroke in humans. Preclinical investigations for AP-188, as part of their stroke clinical research program, are underway through a collaboration with Charles River Laboratories. Established in 2015, Algernon Pharmaceuticals Inc. is headquartered in Vancouver, Canada.
株価
$0.29357476
最終同期: 2026-05-14
時価総額
$1.02M
変化(1日)
1.27%
変化(1年)
-42.07%
CA
取引 Algernon Pharmaceuticals Inc. (AGN)

カテゴリー

Algernon Pharmaceuticals Inc.(AGN)のEPS
2026 時点のEPS TTM: 0
Algernon Pharmaceuticals Inc.の最新の財務報告と株価によると、同社の現在のEPS(TTM)は0です。2026年末には、EPSは0で、2026年のEPS0と同等でした。
Algernon Pharmaceuticals Inc.のEPS履歴(2026から2026まで)
各年末時点のEPS
EPS 変化
提供された日付のデータは十分ではありません。
同様の企業または競合他社のEPS